BRPI0815135A2 - Derivados de azepina como inibidores de gama secretase. - Google Patents
Derivados de azepina como inibidores de gama secretase.Info
- Publication number
- BRPI0815135A2 BRPI0815135A2 BRPI0815135-0A2A BRPI0815135A BRPI0815135A2 BR PI0815135 A2 BRPI0815135 A2 BR PI0815135A2 BR PI0815135 A BRPI0815135 A BR PI0815135A BR PI0815135 A2 BRPI0815135 A2 BR PI0815135A2
- Authority
- BR
- Brazil
- Prior art keywords
- secretase
- azepine derivatives
- inhibitors
- range
- range inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95572007P | 2007-08-14 | 2007-08-14 | |
PCT/US2008/072049 WO2009023453A1 (en) | 2007-08-14 | 2008-08-04 | Azepine derivatives as gamma-secretase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0815135A2 true BRPI0815135A2 (pt) | 2015-02-03 |
Family
ID=39811736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0815135-0A2A BRPI0815135A2 (pt) | 2007-08-14 | 2008-08-04 | Derivados de azepina como inibidores de gama secretase. |
Country Status (11)
Country | Link |
---|---|
US (1) | US8188069B2 (pt) |
EP (1) | EP2178844A1 (pt) |
JP (1) | JP5385904B2 (pt) |
KR (1) | KR101136260B1 (pt) |
CN (1) | CN101778826B (pt) |
AU (1) | AU2008287124B2 (pt) |
BR (1) | BRPI0815135A2 (pt) |
CA (1) | CA2694209C (pt) |
EA (1) | EA017286B1 (pt) |
MX (1) | MX2010001754A (pt) |
WO (1) | WO2009023453A1 (pt) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007334260A1 (en) | 2006-11-15 | 2008-06-26 | Massachusetts Eye & Ear Infirmary | Generation of inner ear cells |
AU2009316264B2 (en) | 2008-11-24 | 2016-09-15 | Massachusetts Eye & Ear Infirmary | Pathways to generate hair cells |
TWI530489B (zh) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯二氮呯酮化合物 |
US20130060023A1 (en) * | 2011-09-07 | 2013-03-07 | Satori Pharmaceuticals, Inc. | Compounds useful for treating neurodegenerative disorders |
US20150209367A1 (en) | 2012-09-07 | 2015-07-30 | Massachusetts Eye & Ear Infirmary | Treating Hearing Loss |
WO2014047390A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds as notch inhibitors |
TWI614238B (zh) | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯并二氮呯酮化合物及其前藥 |
US9133139B2 (en) | 2012-09-21 | 2015-09-15 | Bristol-Myers Squibb Company | Fluoroalkyl-1,4-benzodiazepinone compounds |
JP2015529250A (ja) | 2012-09-21 | 2015-10-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | フルオロアルキルジベンゾジアゼピノン化合物 |
US9427442B2 (en) | 2012-09-21 | 2016-08-30 | Bristol-Myers Squibb Company | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds |
WO2014047393A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors |
US9187434B2 (en) | 2012-09-21 | 2015-11-17 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinones compounds |
CN105308030A (zh) | 2012-09-21 | 2016-02-03 | 百时美施贵宝公司 | 烷基、氟烷基-1,4-苯并二氮杂*酮化合物 |
CN104968648A (zh) | 2012-09-21 | 2015-10-07 | 百时美施贵宝公司 | 1,4-苯并二氮杂*酮化合物的前药 |
JP2016515625A (ja) | 2013-04-04 | 2016-05-30 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 増殖性疾患を治療するための併用療法 |
WO2015073524A1 (en) * | 2013-11-12 | 2015-05-21 | Drexel University | Novel methods of treating or preventing alzheimer's disease |
WO2016022776A2 (en) | 2014-08-06 | 2016-02-11 | Massachusetts Eye And Ear Infirmary | Increasing atoh1 life to drive sensorineural hair cell differentiantion |
EP3212773B1 (en) | 2014-10-29 | 2021-09-15 | Massachusetts Eye and Ear Infirmary | Efficient delivery of therapeutic molecules to cells of the inner ear |
US11185536B2 (en) | 2015-12-04 | 2021-11-30 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss by inhibition of casein kinase 1 |
CN109219439B (zh) | 2016-01-29 | 2022-09-20 | 马萨诸塞眼科耳科诊所 | 内耳支持细胞的扩增和分化及其使用方法 |
WO2017180389A1 (en) | 2016-04-12 | 2017-10-19 | Eli Lilly And Company | Combination therapy with notch and cdk4/6 inhibitors for the treatment of cancer |
JP6911048B2 (ja) | 2016-04-12 | 2021-07-28 | イーライ リリー アンド カンパニー | がんの処置において使用するための、Notch阻害剤およびPI3K/mTOR阻害剤を用いた併用療法 |
KR102362222B1 (ko) | 2016-05-16 | 2022-02-11 | 더 제너럴 하스피탈 코포레이션 | 폐 상피 공학에서 인간 기도 줄기 세포 |
CN109475629A (zh) | 2016-05-20 | 2019-03-15 | 伊莱利利公司 | 用notch和pd-1或pd-l1抑制剂的组合治疗 |
EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
KR20190098998A (ko) | 2016-12-16 | 2019-08-23 | 파이프라인 테라퓨틱스, 아이엔씨. | 달팽이관 시냅스질환의 치료 방법 |
EP4269594A3 (en) | 2017-02-17 | 2023-12-20 | Fred Hutchinson Cancer Center | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
EP3743057A4 (en) | 2018-01-26 | 2021-11-17 | Massachusetts Eye & Ear Infirmary | TREATMENT OF HEARING LOSS |
EP3802611A2 (en) | 2018-06-01 | 2021-04-14 | Novartis AG | Binding molecules against bcma and uses thereof |
JP2022538237A (ja) | 2019-06-24 | 2022-09-01 | ノバルティス アーゲー | B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1616432A (zh) * | 1996-12-23 | 2005-05-18 | 伊兰药品公司 | 化合物、其用途以及含有所述化合物的药物组合物 |
US7468365B2 (en) * | 2000-11-17 | 2008-12-23 | Eli Lilly And Company | Lactam compound |
UA74849C2 (en) | 2000-11-17 | 2006-02-15 | Lilly Co Eli | Lactam |
TW200502221A (en) * | 2002-10-03 | 2005-01-16 | Astrazeneca Ab | Novel lactams and uses thereof |
EP1636196A1 (en) * | 2003-03-14 | 2006-03-22 | AstraZeneca AB | Novel lactams and uses thereof |
-
2008
- 2008-08-04 WO PCT/US2008/072049 patent/WO2009023453A1/en active Application Filing
- 2008-08-04 CN CN2008801030083A patent/CN101778826B/zh not_active Expired - Fee Related
- 2008-08-04 EP EP08827545A patent/EP2178844A1/en not_active Withdrawn
- 2008-08-04 US US12/669,048 patent/US8188069B2/en not_active Expired - Fee Related
- 2008-08-04 EA EA201070278A patent/EA017286B1/ru not_active IP Right Cessation
- 2008-08-04 KR KR1020107002906A patent/KR101136260B1/ko not_active IP Right Cessation
- 2008-08-04 AU AU2008287124A patent/AU2008287124B2/en not_active Ceased
- 2008-08-04 MX MX2010001754A patent/MX2010001754A/es active IP Right Grant
- 2008-08-04 JP JP2010521080A patent/JP5385904B2/ja not_active Expired - Fee Related
- 2008-08-04 CA CA2694209A patent/CA2694209C/en not_active Expired - Fee Related
- 2008-08-04 BR BRPI0815135-0A2A patent/BRPI0815135A2/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EA201070278A1 (ru) | 2010-06-30 |
AU2008287124A1 (en) | 2009-02-19 |
EP2178844A1 (en) | 2010-04-28 |
JP2010536766A (ja) | 2010-12-02 |
JP5385904B2 (ja) | 2014-01-08 |
MX2010001754A (es) | 2010-05-14 |
CN101778826A (zh) | 2010-07-14 |
KR20100032924A (ko) | 2010-03-26 |
KR101136260B1 (ko) | 2012-04-19 |
CA2694209A1 (en) | 2009-02-19 |
CN101778826B (zh) | 2012-10-31 |
EA017286B1 (ru) | 2012-11-30 |
US8188069B2 (en) | 2012-05-29 |
US20100197660A1 (en) | 2010-08-05 |
AU2008287124B2 (en) | 2013-06-06 |
CA2694209C (en) | 2013-09-17 |
WO2009023453A1 (en) | 2009-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0815135A2 (pt) | Derivados de azepina como inibidores de gama secretase. | |
BRPI0812825A2 (pt) | Derivados ftalazinona como inibidores de parp-1 | |
BRPI0906625A2 (pt) | Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace) | |
BRPI1008749A2 (pt) | Derivados de benzodiazepina | |
BRPI0811065A2 (pt) | Indazóis 5-heteroaril substituídos como inibidores de quinase | |
BRPI0920135A2 (pt) | imidazopiridazinacarbonitrilos úteis como inibidores de quinase | |
BRPI0814256A2 (pt) | Inibidores de tetrahidropiranocromeno gama secretase | |
BRPI0810462A2 (pt) | Derivados de quinolina-carboxamida como antagonistas de p2y12 | |
BRPI0906973A2 (pt) | Compostos e composições como inibidores de cinase. | |
BRPI0913879A2 (pt) | fenilpirazinonas como inibidores de quinase | |
BRPI0907435A2 (pt) | Derivados de 5-flúor pirimidina | |
BRPI0813707A2 (pt) | Derivados de pirimidinil-piridazinona | |
BRPI0820112A2 (pt) | Derivados de isoxazol-piridina | |
BRPI0809992A2 (pt) | Derivados de pirrolopirimidina | |
BRPI0820113A2 (pt) | Derivados de isoxazolo-piridazina | |
BRPI0913580A2 (pt) | pirrolopiridinas como inibidores de quinase | |
BRPI0913832A2 (pt) | derivados de pirrolopiridinilpirimidin-2-ilamina | |
BRPI0915064A2 (pt) | derivados de qunoxalinadiona | |
BRPI0812155A2 (pt) | derivados de espiroindolinona | |
BRPI0817935A2 (pt) | Derivados de biarila | |
BRPI0812170A2 (pt) | Moduladores de gama secretase | |
BRPI0813768A2 (pt) | Derivados de benzazepina úteis como antagonistas de vasopressina | |
BRPI0812518A2 (pt) | Derivados de indazolamida | |
BRPI0814236A2 (pt) | Derivados de quinazolinamida | |
BRPI0820649A2 (pt) | Derivados de isoxazalo-pirazina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |